权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Enhancing the Vascularization Properties of Skin Tissue

增强皮肤组织的血管化特性

基本信息

批准号：
7429682
负责人：
Allen R. Comer
金额：
$ 47.8万
依托单位：
STRATATECH CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-01 至 2010-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7429682
关键词：
ARNT protein Agar Angiogenic Factor Animal Model Award Beds Biological Cell Line Cell Survival Cells Chronic Clinical Trials Defect Dermal Development Endothelial Cells Engineering Evaluation Evaluation Research Gene Expression Gene Targeting Generations Genes Genetic Genetic Engineering Goals Growth Growth Factor Healed Homeostasis Human Hypoxia Impaired wound healing Individual Ischemia Karyotype Lead Legal patent Marketing Mediator of activation protein Modeling Modification Nature Necrosis Numbers Oxygen Phase Phase II Clinical Trials Play Positioning Attribute Process Production Property Rate Research Role Safety Series Signal Transduction Skin Skin Substitutes Skin Tissue Source Stratified Squamous Epithelium Therapeutic Tissue Engineering Tissues Transgenic Mice Ulcer United States Food and Drug Administration Vascular Endothelial Growth Factors Vascularization Work Wound Healing angiogenesis cell bank commercialization design enhancing factor healing hypoxia inducible factor 1 improved keratinocyte pathogen pre-clinical tumorigenic wound wound vascularization

项目摘要

DESCRIPTION (provided by applicant): To date no biological treatment options specifically targeting the hypoxic nature of chronic wounds have been developed and marketed. While administration of individual angiogenic factors may stimulate some aspects of angiogenesis, the simultaneous expression of multiple factors is required to promote morphologically and functionally normal vessels. In this Phase II study, we propose to characterize a human keratinocyte cell line genetically-modified to coordinately express elevated levels of multiple therapeutic factors. Advances in ex vivo genetic engineering of a patented human keratinocyte cell line at Stratatech Corporation has made it uniquely positioned to complete this work. If successful, the proposed research will ultimately lead to the development and commercialization of improved treatments to promote the healing of chronic wounds and other severe skin defects.

描述（由申请人提供）：迄今为止，尚未开发和销售专门针对慢性伤口缺氧性质的生物治疗方案。虽然施用单个血管生成因子可以刺激血管生成的某些方面，但是需要多种因子的同时表达来促进形态和功能正常的血管。在这项II期研究中，我们提出了一个人角质形成细胞系的特点，遗传修饰，协调表达多种治疗因子的水平升高。Stratatech公司在获得专利的人类角质形成细胞系的离体基因工程方面取得的进展使其处于独特的位置来完成这项工作。如果成功，拟议的研究将最终导致改进治疗的开发和商业化，以促进慢性伤口和其他严重皮肤缺损的愈合。